货号:A653594
同义名:
NSC 82149; α-Solasonine
Solasonine是一种的铁死亡 (ferroptosis) 诱导剂,通过抑制 GPX4,破坏谷胱甘肽氧化还原反应,促进肝癌细胞铁死亡。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | Solasonine is a natural product isolated and purified from the herbs of Solanum nigrum L. |
| Concentration | Treated Time | Description | References | |
| Pig cecal suspension | 1 µM | 0-24 hours | Investigate the degradation of Solasonine in the pig cecum model. Results showed that Solasonine was completely metabolized within 10 minutes, releasing its aglycone solasodine at a concentration of around 800 nM. Subsequently, the concentration of solasodine gradually decreased over time, reaching 196±252 nM after 24 hours. | ACS Omega. 2023 May 12;8(20):18266-18274 |
| MDA-MB-231 cells | 3 μg/mL | 24 hours | SS inhibits the proliferation, migration, and invasion of MDA-MB-231 cells and activates ferroptosis by inhibiting the ERK2/MAPK signaling pathway. | Cancer Cell Int. 2025 Feb 17;25(1):49 |
| MCF-7 cells | 3 μg/mL | 24 hours | SS inhibits the proliferation, migration, and invasion of MCF-7 cells and activates ferroptosis by inhibiting the ERK2/MAPK signaling pathway. | Cancer Cell Int. 2025 Feb 17;25(1):49 |
| SGC-7901 human gastric cancer cells | 18 µM | 24 hours | Solasonine mainly induced cell cycle arrest at G2 phase in SGC-7901 cells, significantly down-regulated Bcl-2 and Caspase-3 protein expression, and reduced Bax and Bcl-xL protein expression. | J Cell Mol Med. 2022 Jun;26(12):3387-3395 |
| SGC-7901 human gastric cancer cells | 1, 2.5, 5, 10, 20, 30, 50 μg/ml | 24 hours | Solasonine remarkably suppressed the in vitro proliferation of SGC-7901 cells in a dose-dependent manner, with a 24-hour IC50 value of 18 μM, comparable to cisplatin (17.5 μM). | J Cell Mol Med. 2022 Jun;26(12):3387-3395 |
| QGY-7703 cells | 45 µM | 24 hours | Inhibited QGY-7703 cell growth, increased miR-375-3p expression, and decreased lncRNA CCAT1 levels | Front Oncol. 2019 Oct 18;9:1081 |
| HepG2 human hepatocellular carcinoma cells | 45 µM | 24 hours | Inhibited HepG2 cell growth, increased miR-375-3p expression, and decreased lncRNA CCAT1 levels | Front Oncol. 2019 Oct 18;9:1081 |
| A549 cells | 20, 25, 30 µM | 24 hours | To evaluate the effect of Solasonine on the growth of A549 cells, the results showed that Solasonine inhibited cell growth and induced cell death in a dose-dependent manner. | Front Oncol. 2022 May 18;12:874900 |
| Calu-1 cells | 10, 15, 20 µM | 24 hours | To evaluate the effect of Solasonine on the growth of Calu-1 cells, the results showed that Solasonine inhibited cell growth and induced cell death in a dose-dependent manner. | Front Oncol. 2022 May 18;12:874900 |
| MV4-11 | 12.50 µM (IC50) | 24 or 48 hours | Inhibited cell proliferation, promoted apoptosis, and induced G2/M phase cell cycle arrest | Front Oncol. 2021 Jan 29;10:614067 |
| THP-1 | 11.19 µM (IC50) | 24 or 48 hours | Inhibited cell proliferation, promoted apoptosis, and induced G2/M phase cell cycle arrest | Front Oncol. 2021 Jan 29;10:614067 |
| CFPAC-1 cells | 5, 10, 25, 50 µM | 24, 48, 72 hours | Solasonine inhibited the proliferation, migration, and invasion of CFPAC-1 cells and promoted apoptosis. | Front Oncol. 2022 Apr 12;12:834729 |
| PANC-1 cells | 5, 10, 25, 50 µM | 24, 48, 72 hours | Solasonine inhibited the proliferation, migration, and invasion of PANC-1 cells and promoted apoptosis. | Front Oncol. 2022 Apr 12;12:834729 |
| C3H10T1/2 cells | 0.1, 0.3, 0.5, 1, 3, 5 µM | 36 hours | Suppressed ALP activity, reduced mRNA expression of Gli1 and Ptch1 | Molecules. 2016 Oct 14;21(10):1364 |
| Light II cells | 0-5 µM | 36 hours | Inhibited Gli-responsive reporter activity, IC50 value of 1.56 μM | Molecules. 2016 Oct 14;21(10):1364 |
| Raw cells | 10 µM | 48 hours | Evaluate the effect of Solasonine on Raw cells, showing no impact on cell proliferation. | Antimicrob Agents Chemother. 2016 Apr 22;60(5):2732-8 |
| Dendritic cells | 10 µM | 48 hours | Evaluate the killing effect of Solasonine on dendritic cells infected with Leishmania mexicana, showing significant reduction in parasite counts. | Antimicrob Agents Chemother. 2016 Apr 22;60(5):2732-8 |
| Macrophages | 10 µM | 48 hours | Evaluate the killing effect of Solasonine on macrophages infected with Leishmania mexicana, showing significant reduction in parasite counts. | Antimicrob Agents Chemother. 2016 Apr 22;60(5):2732-8 |
| HepG2 cells | 91.8 ± 9.4 µM (IC50) | 72 hours | To evaluate the cytotoxic effect of Solasonine on HepG2 cells, the results showed an IC50 of 91.8 ± 9.4 μM, indicating weaker antiproliferative effects against HepG2 cells. | Sci Rep. 2019 Feb 11;9(1):1746 |
| Huh-7 cells | 10.3 ± 1.5 µM (IC50) | 72 hours | To evaluate the cytotoxic effect of Solasonine on Huh-7 cells, the results showed an IC50 of 10.3 ± 1.5 μM, indicating significant antiproliferative effects against Huh-7 cells. | Sci Rep. 2019 Feb 11;9(1):1746 |
| Administration | Dosage | Frequency | Description | References | ||
| C57BL/6 mice | Cutaneous leishmaniasis model | Topical administration | 10 μM solasonine per mouse per day | Daily administration for 6 weeks | Evaluate the therapeutic effect of Solasonine on cutaneous leishmaniasis, showing significant reduction in lesion sizes and parasite counts. | Antimicrob Agents Chemother. 2016 Apr 22;60(5):2732-8 |
| BALB/c nude mice | Breast carcinoma xenograft model | Oral administration | 20 mg/kg and 40 mg/kg | Twice a week for five weeks | SS activates ferroptosis by inhibiting the ERK2/MAPK signaling pathway, thereby inhibiting the growth and proliferation of breast carcinoma xenografts. | Cancer Cell Int. 2025 Feb 17;25(1):49 |
| BALB/c nude mice | THP-1 cell xenograft model | Intraperitoneal injection | 4, 8, or 16 mg/kg | Once daily for 14 days | Inhibited tumor growth through activation of the AMPK/FOXO3A axis | Toxins (Basel). 2018 Nov 23;10(12):487 |
| BALB/c nude mice | THP-1 cell xenograft model | Intraperitoneal injection | 4, 8, or 16 mg/kg | Once daily for 14 days | Inhibited tumor growth through activation of the AMPK/FOXO3A axis | Front Oncol. 2021 Jan 29;10:614067 |
| Nude mice | Pancreatic cancer xenograft model | Oral administration | 40 or 80 mg/kg | Twice a week for 5 weeks | Solasonine inhibited tumor formation and metastasis and reduced the expression of drug resistance-related proteins (MRP1 and P-gp). | Front Oncol. 2022 Apr 12;12:834729 |
| Nude mice | HepG2-Luc xenograft tumor model | Intraperitoneal injection | 5 mg/kg and 20 mg/kg | Once daily for 15 days | Inhibited HepG2-Luc xenograft tumor growth, increased miR-375-3p expression, and decreased CCAT1, SP1, and IRF5 levels | Front Oncol. 2019 Oct 18;9:1081 |
| Galleria mellonella | Larvae | Diet | Three concentrations: SolA (1.49×10⁻³ mg/1 g diet), SolB (7.465×10⁻⁴ mg/1 g diet), SolC (3.825×10⁻⁴ mg/1 g diet) | Three days | To evaluate the effects of S. nigrum extract and solasonine on the physiology of G. mellonella larvae. Results showed that solasonine altered hemolymph metabolites and the ultrastructure of fat body and midgut cells. | Toxins (Basel). 2021 Sep 1;13(9):617 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.13mL 0.23mL 0.11mL |
5.66mL 1.13mL 0.57mL |
11.31mL 2.26mL 1.13mL |
|
| CAS号 | 19121-58-5 |
| 分子式 | C45H73NO16 |
| 分子量 | 884.06 |
| SMILES Code | O[C@H]1[C@H](O[C@H]2[C@@H](O)[C@@H](CO)O[C@@H](O[C@@H]3CC4=CC[C@@]5([H])[C@]6([H])C[C@]7([H])O[C@@]8(NC[C@H](C)CC8)[C@@H](C)[C@]7([H])[C@@]6(C)CC[C@]5([H])[C@@]4(C)CC3)[C@@H]2O[C@H]9[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O9)O[C@H](CO)[C@@H](O)[C@@H]1O |
| MDL No. | MFCD00017611 |
| 别名 | NSC 82149; α-Solasonine |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, sealed in dry, 2-8°C |
| 溶解方案 |
DMSO: 105 mg/mL(118.77 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1